Avalo Therapeutics Inc (AVTX) - News Archive

The therapeutic landscape for hidradenitis suppurativa (HS), a debilitating chronic inflammatory skin condition, has been markedly stagnant until recent advances in biotechnology. At the forefront of this change is Aval...

: Avalo Therapeutics, Inc. has initiated its Phase 2 LOTUS trial, marking a significant advancement in the development of AVTX-009, a humanized monoclonal antibody aimed at treating hidradenitis suppurativa (HS). This a...

In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009...

In a strategic move to further strengthen its leadership team, Avalo Therapeutics, Inc. (Nasdaq: AVTX) proudly announced the appointment of Paul Varki as its new Chief Legal Officer. Varki brings with him a wealth of ex...

Breaking News: Avalo Therapeutics Reports Strong 2023 Results and Exciting Business UpdatesWAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 - Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading biotechnology company special...

Avalo Therapeutics Inc. Bolsters Pipeline with Acquisition of AVTX-009 and Secures $185 Million in Private Placement FundingIn a recent press release, Avalo Therapeutics Inc. (Nasdaq: AVTX) announced the acquisition of...

IntroductionAvalo Therapeutics, Inc. (Nasdaq: AVTX) has recently called on its stockholders to actively participate in the adjourned annual meeting of stockholders. The meeting, initially held on December 5, 2023, lacke...